Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Post-hoc analysis found canagliflozin reduced the rate of investigator-reported anaemia or treatment for anaemia vs placebo (HR 0.65, 95%CI 0.55-0.77). There were also lower risks of anaemia events, initiation of iron preparations and need for erythropoiesis-stimulating agents.

The Lancet Diabetes & Endocrinology